Assessment of Color Vision in Diabetic Patients

• Sponsor: Instituto de Olhos de Goiania (Other)
• Overall Status: Completed
• CT.gov ID: NCT03345667
• Collaborator: (none)
• Enrollment: 30
• Location: 1
• Actual Duration (Months): 3
• Patients Per Site Per Month: 10.1

Study Details

Study Description

Brief Summary

Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema

Condition or Disease	Intervention/Treatment	Phase
Retinopathy, Diabetic	Drug: lucentis

Study Design

• Study Type: Observational
• Actual Enrollment: 30 participants
• Observational Model: Ecologic or Community
• Time Perspective: Retrospective
• Official Title: Assessment of Color Vision in Diabetic Patients Before and After the Use of Anti-vegf in the Treatment of Diabetic Macular Edema
• Actual Study Start Date: Aug 1, 2017
• Actual Primary Completion Date: Oct 1, 2017
• Actual Study Completion Date: Oct 30, 2017

Arms and Interventions

Arm	Intervention/Treatment
Anti-Vegf Use intravitreous anti-vegf	Drug: lucentis; Use of lucentis and other anti-vegf in patients with diabetic retinopathy

Outcome Measures

Primary Outcome Measures

1. Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema [3 months]

   Using the Ishihara's test to analise the possible loss of vision

Secondary Outcome Measures

1. Frame between the injections [1 months]

   Ant-Vegf

Eligibility Criteria

Criteria

• Ages Eligible for Study: 1 Year to 100 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Having diabetic retinopathy with macular edema

Exclusion Criteria:

• Not having diabetic retinopathy with macular edema

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Instituto de Olhos de Goiania	Goiânia	Goias	Brazil	74110120

Sponsors and Collaborators

• Instituto de Olhos de Goiania

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Instituto de Olhos de Goiania
• ClinicalTrials.gov Identifier: NCT03345667
• Other Study ID Numbers: TRABALHO PEDRO ARVO 2018
• First Posted: Nov 17, 2017
• Last Update Posted: Nov 17, 2017
• Last Verified: Nov 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Diabetic Retinopathy; Ranibizumab

Study Results

No Results Posted as of Nov 17, 2017